MRK•benzinga•
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
Summary
Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access to delivery technology.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 15, 2025 by benzinga